Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629 1649 1675
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17787152 | STABILIZATION OF MHC COMPLEXES | Non-Final OA | The Regents of the University of California |
| 16993434 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18339960 | METHODS FOR TREATING MULTIPLE SCLEROSIS WITH OCRELIZUMAB | Non-Final OA | Hoffmann-La Roche Inc. |
| 17047497 | METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT | Final Rejection | The Cleveland Clinic Foundation |
| 17689867 | Epigenomic editing and reactivation of targets for the treatment of Fragile X syndrome | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17272124 | COMPOSITIONS AND METHODS OF USING CELL-PENETRATING ANTIBODIES IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | Final Rejection | Yale University |
| 17276757 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | Non-Final OA | SUTRO BIOPHARMA, INC. |
| 17917174 | CROSS-REACTIVE CORONAVIRUS ANTIBODIES AND USES THEREOF | Final Rejection | TRUSTEES OF DARTMOUTH COLLEGE |
| 17623238 | CD38-BINDING AGENTS AND USES THEREOF | Non-Final OA | Biohaven Therapeutics Ltd. |
| 17920055 | INTERFERON ALPHA 2 VARIANTS AND USES THEREOF | Non-Final OA | UNIVERSITAET DUISBURG-ESSEN |
| 17792378 | FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE | Final Rejection | The United States of America, as represented by the Secretary, Department of Health and Human Serv |
| 17769916 | Extended Half-life G-CSF and GM-CSF Vitamin D Conjugates | Non-Final OA | RAMEA LLC |
| 16629877 | POTASSIUM CHANNEL INHIBITORS | Final Rejection | MAXION THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy